Tunbridge Wells, United Kingdom, October 08, 2014 --(PR.com
)-- Asthma is a chronic inflammatory disorder of the airways affecting over 300 million people globally, with symptoms that cause 15 million disability-adjusted life-years (DALYs) to be lost each year. Identifying and tackling the specific symptoms of individual patients is a critical part of accomplishing disease control and the launch of a new interactive online educational resource is designed to support healthcare professionals (HCPs) in doing just that.
Studies show that patients have low expectations of asthma treatments and tend to accept that their quality of life will be much worse than guidelines state they should be, with 69% of patients restricted in their physical activities.
Focusing on the lack of symptomatic control in patients with asthma, the new Symptomatic Asthma Knowledge Centre is hosted on disease and medicines knowledge base www.epgonline.org. It is free to access for respiratory specialists, general practitioners and other HCPs worldwide.
“This resource provides valuable educational materials, tools, guidelines and techniques for assessing asthma control and achieving optimal treatment outcomes for symptomatic patients," said Chris Cooper, publisher of epgonline.org. "Thanks to support from our partner, Boehringer Ingelheim, users of epgonline.org are now able to benefit from free access to the latest best practice guidance on tackling the burden of symptomatic asthma”
“Boehringer Ingelheim remains committed to supporting continuing and independent medical education, and is proud to partner with EPG.”
Notes To Editors
About EPG Health Media and epgonline.org
Published by EPG Health Media (Europe), epgonline.org is an independent website dedicated to providing healthcare professionals with free access to the most recent, best practice diagnosis and patient management guidance. In addition to the library of disease Knowledge Centres, the website includes a database of prescription drugs in 9 European languages, clinical trial reports, treatment guidelines, medical news, journal abstracts, multimedia, and apps; all arranged around 50 disease topic areas.
For more information please visit www.epghealthmedia.com.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.
In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.
For more information please visit www.boehringer-ingelheim.com
Further Media Channels:
1. World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. 2007. Available from: http://www.who.int/gard/publications/GARD%20Book%202007.pdf
2. Global Initiative for Asthma. Global burden of asthma, 2004. Available from: http://www.ginasthma.org/local/uploads/files/GINABurdenReport_1.pdf.
3. Haughney J et al. The Living & Breathing Study: a study of patient’ views of asthma and its treatment. Prim Care Respir J. 2004;13:28–35.
4. Dockrell M, et al. The limitations of severe asthma: the results of a European survey. Allergy. 2007;62:134–141.
EPG Health Media
Royal Victoria House
51-55 The Pantiles
Kent TN2 5TE
Tel: 01892 526 776
Fax: 01892 527 669